Bausch + Lomb Corporation (BLCO) Discusses Glaucoma Pipeline Focus With Updates on BL1107 and Elios Transcript

Bausch + Lomb held an investor call on March 23, 2026 focusing on its glaucoma pipeline, specifically BL-1107 (an alpha-2b agonist) and ELIOS (an excimer laser), with management providing development updates. The presentation was descriptive and strategic—no trial results, approvals, or financial guidance were announced.

Analysis

BLCO's move into an excimer-based glaucoma therapy and a novel topical alpha-2b agent shifts the company's margin profile toward recurring procedural and consumable revenue rather than one-time drug sales. If the device achieves procedure volumes similar to SLT in parts of the U.S. and EU, a 5-8% uplift to pharma-adjusted gross margins is plausible within 24-36 months because lasers carry high attach rates for disposables, service contracts and upgrade revenue. Laser-component suppliers and optical OEMs (UV lamps, precision optics, control electronics) will see earlier revenue flow — expect channel inventory and service revenues to materialize 6-12 months before meaningful device sales arrive to clinics.

The primary near-term binary risks are clinical/regulatory readouts and reimbursement coding — both operate on 6-18 month timetables and can flip valuation momentum quickly. Adoption risk is non-trivial: SLT and MIGS compete on capital intensity and throughput; a failure to demonstrate superior safety, durable IOP lowering, or a clear workflow advantage will cap uptake and favor cheaper office-based alternatives. Also consider surgical training friction and ASC capital cycles: a recessionary environment or tighter hospital budgets could push installations out by 12-24 months, delaying revenue recognition.

From a portfolio perspective the market likely underestimates BLCO's ability to monetize consumables globally through existing distribution, creating an asymmetric payoff if early clinician enthusiasm converts to procedure growth. Conversely, consensus may overstate speed of displacement of entrenched therapies; patience is required. Tactical exposure should be structured to capture regulatory and early-adoption binaries while capping downside from trial or reimbursement setbacks.

Key Decisions for Investors

• Long BLCO equity (or buy Jan 2027 call spreads) sized 2-3% of the portfolio to capture upside from regulatory milestones and early commercial traction; prefer call spreads to cap premium decay — target 2-4x payoff if BLCO secures favorable reimbursement and 12-18 month uptake.
• Pair trade: long BLCO / short GKOS (or a MIGS-centric ETF) for 12-24 months — rationale: if ELIOS wins share from microinvasive devices this spread benefits; risk: GKOS holds other franchises and sector-wide device weakness could hurt both.
• Long suppliers of UV/laser optics (e.g., LITE or IPGP-like names) via 6-12 month call spreads to play near-term supply-chain revenue pickup; limited premium at risk, asymmetric upside if OEM deployments accelerate.
• Risk hedge: buy out-of-the-money put protection on BLCO over next 9-12 months sized at 0.5-1% of the book to guard against trial failure or adverse reimbursement decisions that would compress multiple sharply.